title: Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism.
abstract: BACKGROUND
  When administered chronically to rats, drugs that are effective in bipolar disorder-lithium and the anticonvulsants, valproic acid and carbamazepine-have been shown to downregulate the expression of certain enzymes involved in brain arachidonic acid (AA) release and cyclooxygenase (COX)-mediated metabolism. Phase II clinical trials with the anticonvulsant topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate] suggest that this drug may also be effective for bipolar disorder.
  
  
  OBJECTIVE
  To see if topiramate has effects similar to those of the other three drugs, we administered topiramate to rats for 14 days at 20 mg/kg, p.o. twice daily.
  
  
  RESULTS
  Compared with p.o. vehicle, topiramate treatment did not significantly affect the brain activity or protein level of cytosolic phospholipase A2, secretory PLA2, or Ca2+-independent iPLA2. Additionally, brain protein levels of COX-1, COX-2, 5-lipoxygenase, and cytochrome P450 epoxygenase were unchanged.
  
  
  CONCLUSIONS
  These results suggest that topiramate does not modify expression of the enzymes involved in brain AA metabolism that have been shown to be targeted by lithium, valproic acid, or carbamazepine. If topiramate proves effective in bipolar disorder, it may not act by modulating brain AA metabolism. In view of the proven anticonvulsant effect of topiramate, our results also suggest that the AA cascade is not involved in the anti-seizure properties of the drug.
authors.affiliation: Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Bldg. 10, Rm. 6N202, Bethesda, MD 20892, USA.
authors.forename: Sandra
authors.initials: S
authors.lastname: Ghelardoni
authors.forename: Richard P
authors.initials: RP
authors.lastname: Bazinet
authors.forename: Stanley I
authors.initials: SI
authors.lastname: Rapoport
authors.forename: Francesca
authors.initials: F
authors.lastname: Bosetti
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D015153:Blotting, Western; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007124:Immunoenzyme Techniques; D020738:Leptin / Q000097:blood; D008297:Male; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors; D000077236:Topiramate
chemical_list: D020738:Leptin; D000077236:Topiramate; D016718:Arachidonic Acid; D005632:Fructose; D011451:Prostaglandin-Endoperoxide Synthases; D010741:Phospholipases A; D054467:Phospholipases A2
references.citation: J Clin Psychopharmacol. 2002 Aug;22(4):431-5
references.pmid: 12172346
references.citation: J Clin Psychiatry. 2004 Jan;65(1):10-21
references.pmid: 14744163
references.citation: Pharmacotherapy. 1995 Sep-Oct;15(5):631-47
references.pmid: 8570437
references.citation: Neurochem Res. 1999 Mar;24(3):399-406
references.pmid: 10215514
references.citation: Brain Res Bull. 2004 Jul 15;63(6):485-9
references.pmid: 15249113
references.citation: Br J Pharmacol. 2003 Jul;139(5):1014-22
references.pmid: 12839876
references.citation: J Peripher Nerv Syst. 2004 Jun;9(2):70-8
references.pmid: 15104694
references.citation: Biochem Soc Trans. 2004 Nov;32(Pt 5):799-802
references.pmid: 15494019
references.citation: Epilepsia. 2000;41 Suppl 1:S40-4
references.pmid: 10768299
references.citation: Neuropharmacology. 2002 Dec;43(7):1158-64
references.pmid: 12504922
references.citation: Med J Aust. 1949 Sep 3;2(10):349-52
references.pmid: 18142718
references.citation: Epilepsia. 2000;41 Suppl 1:S52-60
references.pmid: 10768302
references.citation: J Neurosci. 2003 Aug 6;23(18):7069-74
references.pmid: 12904467
references.citation: J Neurochem. 1990 Jul;55(1):1-15
references.pmid: 2113081
references.citation: J Neural Transm (Vienna). 2002 Mar;109(3):433-40
references.pmid: 11956963
references.citation: Eur J Pharmacol. 2002 Aug 23;450(2):141-51
references.pmid: 12206852
references.citation: J Neurochem. 2004 Jan;88(2):320-5
references.pmid: 14690520
references.citation: J Neurochem. 2003 May;85(3):690-6
references.pmid: 12694395
references.citation: Neuroreport. 2001 Apr 17;12(5):1031-4
references.pmid: 11303740
references.citation: Biol Psychiatry. 2000 Jun 15;47(12):1025-33
references.pmid: 10862801
references.citation: J Mol Neurosci. 2001 Apr-Jun;16(2-3):243-61; discussion 279-84
references.pmid: 11478380
references.citation: Nutrition. 2000 Oct;16(10 ):967-75
references.pmid: 11054603
references.citation: Psychopharmacol Bull. 2003 Winter;37(1):47-63
references.pmid: 14561948
references.citation: Arch Gen Psychiatry. 2002 Jul;59(7):592-6
references.pmid: 12090811
references.citation: J Clin Invest. 2001 Jun;107(11):1347-51
references.pmid: 11390414
references.citation: Neurosci Lett. 1996 Dec 20;220(3):171-4
references.pmid: 8994220
references.citation: Psychopharmacology (Berl). 1995 Dec;122(4):363-8
references.pmid: 8657834
references.citation: Epilepsia. 2000;41 Suppl 1:S3-9
references.pmid: 10768292
references.citation: Bipolar Disord. 2002 Jun;4(3):207-13
references.pmid: 12180276
references.citation: Trends Neurosci. 1995 Feb;18(2):64-5
references.pmid: 7537411
references.citation: Neuropharmacology. 2002 Feb;42(2):210-20
references.pmid: 11804617
references.citation: Ann Clin Psychiatry. 2002 Dec;14(4):223-32
references.pmid: 12630658
references.citation: Mol Psychiatry. 2002;7(8):845-50
references.pmid: 12232777
references.citation: J Clin Psychopharmacol. 1992 Feb;12(1 Suppl):42S-52S
references.pmid: 1541717
references.citation: J Psychosom Res. 1996 Jan;40(1):53-8
references.pmid: 8730644
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Neuroreport. 1999 Dec 16;10 (18):3887-90
references.pmid: 10716228
references.citation: Br J Pharmacol. 2004 Jan;141(2):285-301
references.pmid: 14691058
references.citation: J Neurochem. 2001 May;77(3):796-803
references.pmid: 11331408
references.citation: J Neurochem. 2003 Jun;85(6):1553-62
references.pmid: 12787074
references.citation: Epilepsia. 2000;41 Suppl 1:S10-6
references.pmid: 10768293
references.citation: Biol Psychiatry. 2004 Aug 15;56(4):248-54
references.pmid: 15312812
references.citation: Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):37-54
references.pmid: 11812506